Purpose

Tri-weekly carboplatin is an established neoadjuvant treatment for triple-negative breast cancer, enhancing pathological complete response (pCR) and overall survival. This study explores if weekly carboplatin provides lower toxicity and comparable pCR rates.

Methods/patients

A retrospective multicenter study (January 2021 to March 2023) compares outcomes of weekly and tri-weekly carboplatin.

Results

Among 104 participants, 60% received weekly and 40% tri-weekly treatments. Weekly administration had fewer discontinuations (56.5 vs. 70.7%, p = 0.154). Both schedules exhibited similar overall toxicity (p = 0.087), with slightly higher grade 3–4 toxicity in the tri-weekly group (56.1 vs. 48.4%, p = 0.126). Hematological toxicity was comparable, but the weekly group experienced more diarrhea (p = 0.432) and asthenia (p = 0.012). Weekly treatment correlated with more frequent breast-conserving surgeries (p = 0.004). pCR rates were 50% with weekly and 61% with tri-weekly regimens (p = 0.186).

Conclusions

Weekly carboplatin exhibited comparable toxicity, a trend toward fewer interruptions, and similar pCR rates. Prospective studies are essential for validating these findings.

中文翻译：

---

每周和三周新辅助卡铂治疗三阴性乳腺癌的比较研究：现实环境中的回顾性分析

目的

每三周一次的卡铂是一种成熟的三阴性乳腺癌新辅助治疗方法，可增强病理完全缓解 (pCR) 和总体生存率。本研究探讨每周卡铂是否能提供较低的毒性和可比较的 pCR 率。

方法/患者

一项回顾性多中心研究（2021 年 1 月至 2023 年 3 月）比较了每周和每三周卡铂的结果。

结果

在 104 名参与者中，60% 的人每周接受一次治疗，40% 的人每三周接受一次治疗。每周给药的停药率较低（56.5% vs. 70.7%，p  = 0.154）。两种方案均表现出相似的总体毒性（p  = 0.087），三周组的 3-4 级毒性略高（56.1% vs. 48.4%，p  = 0.126）。血液学毒性相当，但每周组出现更多腹泻 ( p  = 0.432) 和乏力 ( p  = 0.012)。每周治疗与更频繁的保乳手术相关（p  = 0.004）。每周治疗方案的 pCR 率为 50%，每三周治疗方案的 pCR 率为 61% ( p  = 0.186)。

结论

每周卡铂表现出相似的毒性、减少中断的趋势以及相似的 pCR 率。前瞻性研究对于验证这些发现至关重要。